[go: up one dir, main page]

SMT201400008B - Uso di betanecolo per il trattamento di xerostomia - Google Patents

Uso di betanecolo per il trattamento di xerostomia

Info

Publication number
SMT201400008B
SMT201400008B SM201400008T SM201400008T SMT201400008B SM T201400008 B SMT201400008 B SM T201400008B SM 201400008 T SM201400008 T SM 201400008T SM 201400008 T SM201400008 T SM 201400008T SM T201400008 B SMT201400008 B SM T201400008B
Authority
SM
San Marino
Prior art keywords
bethanecol
xerostomia
treatment
Prior art date
Application number
SM201400008T
Other languages
English (en)
Italian (it)
Inventor
Nicola Cooper
Julian Clive Gilbert
Robert William Gristwood
Micheal Grant Wyllie
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0919822A external-priority patent/GB0919822D0/en
Priority claimed from GBGB1004445.1A external-priority patent/GB201004445D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of SMT201400008B publication Critical patent/SMT201400008B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201400008T 2009-11-12 2014-01-22 Uso di betanecolo per il trattamento di xerostomia SMT201400008B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0919822A GB0919822D0 (en) 2009-11-12 2009-11-12 The treatment of salivary gland dysfunction
GBGB1004445.1A GB201004445D0 (en) 2010-03-17 2010-03-17 The treatment of salivary gland dysfunction
PCT/GB2010/051887 WO2011058366A1 (fr) 2009-11-12 2010-11-11 Utilisation de béthanécol pour le traitement de la xérostomie

Publications (1)

Publication Number Publication Date
SMT201400008B true SMT201400008B (it) 2014-03-07

Family

ID=43382322

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400008T SMT201400008B (it) 2009-11-12 2014-01-22 Uso di betanecolo per il trattamento di xerostomia

Country Status (23)

Country Link
US (3) US9149454B2 (fr)
EP (1) EP2498771B1 (fr)
JP (1) JP5595513B2 (fr)
KR (1) KR20120092152A (fr)
CN (1) CN102711752B (fr)
AU (1) AU2010317747B2 (fr)
BR (1) BR112012011086A2 (fr)
CA (1) CA2780256A1 (fr)
CY (1) CY1114766T1 (fr)
DK (1) DK2498771T3 (fr)
EA (1) EA022040B1 (fr)
ES (1) ES2443847T3 (fr)
HR (1) HRP20140020T1 (fr)
IL (1) IL219613A (fr)
MX (1) MX2012005456A (fr)
NZ (1) NZ599880A (fr)
PL (1) PL2498771T3 (fr)
PT (1) PT2498771E (fr)
RS (1) RS53124B (fr)
SI (1) SI2498771T1 (fr)
SM (1) SMT201400008B (fr)
WO (1) WO2011058366A1 (fr)
ZA (1) ZA201203289B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
EP4400130A3 (fr) 2015-02-18 2024-10-16 Insulet Corporation Dispositifs de distribution et de perfusion de fluide
JP6472722B2 (ja) * 2015-06-30 2019-02-20 サンスター株式会社 口腔内投与する唾液分泌促進剤
WO2017123525A1 (fr) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. Interface utilisateur pour système de gestion du diabète
EP3443998B1 (fr) 2016-01-14 2025-03-26 Insulet Corporation Adaptation des valeurs d'insuline
EP3402548B1 (fr) 2016-01-14 2025-03-12 Insulet Corporation Résolution d'occlusion dans des dispositifs, des systèmes et des procédés d'administration de médicaments
US12383166B2 (en) 2016-05-23 2025-08-12 Insulet Corporation Insulin delivery system and methods with risk-based set points
WO2018058041A1 (fr) 2016-09-23 2018-03-29 Insulet Corporation Dispositif d'administration de fluide avec capteur
CA3037432A1 (fr) 2016-12-12 2018-06-21 Bigfoot Biomedical, Inc. Alarmes et alertes pour dispositifs d'administration de medicament et systemes et procedes associes
US11033682B2 (en) 2017-01-13 2021-06-15 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881792B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
KR20200118128A (ko) * 2018-02-05 2020-10-14 셀릭스 바이오 프라이빗 리미티드 항무스카린제 또는 항콜린제 및 리포산의 조합 및 이의 용도
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
EP3788628B1 (fr) 2018-05-04 2024-12-11 Insulet Corporation Contraintes de sécurité pour un système d'administration de médicament basé sur un algorithme de commande
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
WO2020138559A1 (fr) * 2018-12-28 2020-07-02 경상대학교병원 Composition pharmaceutique et aliment fonctionnel de santé pour la prévention ou le traitement de l'hyposalivation
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
KR20210044714A (ko) 2019-10-15 2021-04-23 인하대학교 산학협력단 노화기인 타액선 기능손상 회복을 위한 혈소판 풍부 혈장 기반 치료 조성물
WO2021113647A1 (fr) 2019-12-06 2021-06-10 Insulet Corporation Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
EP4088286A1 (fr) 2020-01-06 2022-11-16 Insulet Corporation Prédiction d'événements de repas et/ou d'exercice sur la base de résidus persistants
EP4100958A1 (fr) 2020-02-03 2022-12-14 Insulet Corporation Utilisation d'une logique floue pour prédire un comportement d'utilisateur affectant la glycémie
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
EP4106716A4 (fr) 2020-02-18 2024-03-13 Sunstar Americas, Inc. Composition de soin buccal
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
WO2022020197A1 (fr) 2020-07-22 2022-01-27 Insulet Corporation Paramètres de base pour l'administration d'insuline en boucle ouverte fondée sur des enregistrements d'administration d'insuline
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
WO2022072332A1 (fr) 2020-09-30 2022-04-07 Insulet Corporation Dispositif d'administration de médicament à glucomètre optique intégré
EP4221588A1 (fr) 2020-09-30 2023-08-09 Insulet Corporation Communications sans fil sécurisées entre un dispositif de surveillance de glucose et d'autres dispositifs
WO2022080529A1 (fr) * 2020-10-15 2022-04-21 경상대학교병원 Composition pharmaceutique et aliment fonctionnel de santé pour prévenir ou traiter l'hyposalivation
US11160925B1 (en) 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic
WO2022192482A1 (fr) 2021-03-10 2022-09-15 Insulet Corporation Dispositif d'administration de médicament ayant une composante de coût de niveau d'analyte réglable et par segments pour répondre aux écarts de niveau d'analyte positifs persistants
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US12406760B2 (en) 2021-06-07 2025-09-02 Insulet Corporation Exercise safety prediction based on physiological conditions
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
CN120457493A (zh) 2023-01-06 2025-08-08 英赛罗公司 自动或手动启动的随餐推注输送及随后的自动安全约束放宽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102340D0 (sv) 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ZA9610154B (en) 1995-12-12 1997-06-17 Universiteit Van Preporia Mouthwash
GB9618341D0 (en) 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
EP1250927A3 (fr) * 1997-02-24 2003-03-26 S.L.A. Pharma AG Composition pharmaceutique comprenant de la nifedipine pour application topique
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
WO2007092811A2 (fr) * 2006-02-07 2007-08-16 Whitehill Oral Technologies, Inc. Articles pour les soins de la bouche, renfermant un sialagogue
JP2010518086A (ja) * 2007-02-09 2010-05-27 デュレクト コーポレーション スフェンタニルおよびナロキソンを含む経口腔投与製剤

Also Published As

Publication number Publication date
AU2010317747A1 (en) 2012-05-31
PL2498771T3 (pl) 2014-03-31
PT2498771E (pt) 2014-01-30
US9149454B2 (en) 2015-10-06
US20160287512A1 (en) 2016-10-06
HRP20140020T1 (hr) 2014-02-14
IL219613A (en) 2016-12-29
IL219613A0 (en) 2012-07-31
DK2498771T3 (da) 2014-01-27
CY1114766T1 (el) 2016-12-14
BR112012011086A2 (pt) 2016-07-05
ZA201203289B (en) 2013-09-25
US20120232137A1 (en) 2012-09-13
CN102711752B (zh) 2014-06-18
EA201270619A1 (ru) 2012-12-28
US20150366794A1 (en) 2015-12-24
SI2498771T1 (sl) 2014-04-30
EA022040B1 (ru) 2015-10-30
MX2012005456A (es) 2012-06-19
JP2013510840A (ja) 2013-03-28
CN102711752A (zh) 2012-10-03
JP5595513B2 (ja) 2014-09-24
EP2498771B1 (fr) 2013-12-25
AU2010317747B2 (en) 2013-10-17
US10137084B2 (en) 2018-11-27
CA2780256A1 (fr) 2011-05-19
RS53124B (en) 2014-06-30
KR20120092152A (ko) 2012-08-20
WO2011058366A1 (fr) 2011-05-19
ES2443847T3 (es) 2014-02-20
NZ599880A (en) 2014-03-28
EP2498771A1 (fr) 2012-09-19

Similar Documents

Publication Publication Date Title
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI1007494A2 (pt) composto e uso do mesmo
HRP20170936T1 (hr) Alkilamido spojevi i njihova uporaba
SMT201800509T1 (it) Uso di inibitori di pde7 per il trattamento di disturbi del movimento
BRPI1012728A2 (pt) uso de tripeptídeos
ITMI20080898A1 (it) Uso di batteri probiotici per il trattamento della iperomocisteinemia
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
BRPI1011036A2 (pt) uso
CO6781486A2 (es) Compuestos y su uso
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
BR112013013551A2 (pt) composto e uso médico do mesmo
IT1403282B1 (it) Procedimento per la preparazione di linagliptin
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
BR112012001837A2 (pt) uso de fulvestrant
FI20100404A0 (fi) Yhteysalus
BR112014010432A2 (pt) uso médico
BRPI1009090A2 (pt) composto, pró-droga, medicamento, métodos, e, uso do composto
BRPI0822637A2 (pt) Uso de lanosta-8, 24-dien-3-óis
IT1400185B1 (it) Chiusura per accessori di uso personale